Crossmark

Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia

Crossref DOI link: https://doi.org/10.1007/s12032-019-1253-5

Published Online: 2019-02-22

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alves, Raquel

Gonçalves, Ana Cristina

Jorge, Joana

Alves, Joana

Alves da Silva, António

Freitas-Tavares, Paulo

Nascimento Costa, José M.

Almeida, António M.

Sarmento-Ribeiro, Ana B. https://orcid.org/0000-0002-4142-4841
Funding

Funding for this research was provided by:

Fundação para a Ciência e a Tecnologia (SFRH/BD/51994/2012)

Center of Investigation on Environment, Genetics and Oncobiology (Project 18/12)

FEDER through the Operational Program Competitiveness Factors – COMPETE and FCT (CNC.IBILI, Center Reference: UID/NEU/04539/2013)
License Information

Text and Data Mining valid from 2019-02-22
More Information

Article History

Received: 10 December 2018

Accepted: 31 January 2019

First Online: 22 February 2019

Compliance with ethical standards

:

: The authors declare that they have no conflicts of interests.